IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA
March 28, 2012
CEPHALON, INC., ET AL., DEFENDANTS.
The opinion of the court was delivered by: Mitchell S. Goldberg, J.
ORDER AND JUDGMENT
AND NOW, this 28th day of March, 2012, following a bench trial, and after careful review of the parties' briefs, for the reasons set out in the Memorandum Opinion filed this day, it is hereby ORDERED that:
1. Defendant Cephalon, Inc.'s "Motion to Preclude Certain Expert Testimony of Dr. David Beach" (Doc. No. 465) is DENIED as MOOT;
2. Defendant Cephalon, Inc.'s Motion for An Adverse Inference (Doc. No. 468), and Apotex, Inc.'s "Motion to Exclude Cephalon, Inc.'s Expert Reports and Testimony Regarding Testing on Modafinil Tablets" (Doc. No. 470) are DENIED; and
3. Judgment is entered in favor of Plaintiff, Apotex, Inc., as to Count III of the Second Amended Complaint (Doc. 195). The Court finds that the manufacture, sale or use of the modafinil product described in Abbreviated New Drug Application No. 77-667 will NOT INFRINGE United States Reissue Patent Number RE 37,516.
BY THE COURT:
Mitchell S. Goldberg
© 1992-2012 VersusLaw Inc.